Virus Like Particles (VLPs) are synthetic particles that mimic the structure of a virus, but lack the genetic material that makes them infectious. VLPs are used in biotechnology for a variety of applications, including vaccine development, drug delivery, and diagnostics. VLPs are produced by expressing viral proteins in a host cell, such as bacteria, yeast, or mammalian cells. This process results in the assembly of the proteins into a particle that closely resembles the native virus.
VLPs are attractive for vaccine development because they can induce a strong immune response without the risk of causing an infection. They can also be used to deliver drugs or other molecules to specific cells or tissues. VLPs are also used in diagnostics, as they can be engineered to bind to specific molecules, allowing them to be used as a detection tool.
Companies in the VLP market include Novavax, Inc., Inovio Pharmaceuticals, Inc., and Vaxart, Inc. Show Less Read more
